[1] Nicolas MI, Stephen HC, Armando T. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology, 2019, 156(6):1582-1599. [2] Jerry LS. Myeloproliferative neoplasms. N Engl J Med,2017, 376(22):2168-2181. [3] Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer, 2007, 7(9):673-683. [4] 夏亮,丁凯阳,蔡晓燕,等. 骨髓增殖性肿瘤患者JAK2V617F基因突变与血栓栓塞相关性研究. 中华血液学杂志,2010,31(9):590-593. [5] Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood, 2012,120(25): 4921-4928. [6] Jiahao F, et al. Prevalence of prothrombotic factors in patients with Budd-Chiari syndrome or non-cirrhotic nonmalignant portal vein thrombosis: a hospital-based observational study. J Gastroenterol Hepatol, 2020,35(7):1215-1222. [7] How J, Zhou A, Oh ST. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Ther Adv Hematol, 2017,8(3):107-118. |